Senhwa's CX-5461 Opens a New Frontier in Photoimmunotherapy; Multinational Study Published in Nucleic Acids Research

TAIPEI and SAN DIEGO, Aug. 12, 2026 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492) today announced a significant research advance involving its investigational drug Pidnarulex (CX-5461). A multinational research team comprising investigators from Poland, Slovakia, France and Senhwa Biosciences in Taiwan found that, under specific cell-based experimental conditions, controlled light activation increased the cancer-cell-killing activity of CX-5461 by up to 96-fold and induced immunogenic cell death (ICD). The findings, published in the peer-reviewed journal Nucleic Acids Research, reveal that CX-5461 may have potential applications in photodynamic therapy and photoimmunotherapy in addition to its established research profile involving G-quadruplex (G4) targeting and DNA-damage-related mechanisms. The study opens a potential new development path for this clinical-stage asset.